Colgate-Palmolive (NYSE: CL) is a new buy from Nilus Mattive. The editor of Dividend Superstars states, "The time is right to add this great consumer products firm to our portfolio."

"Colgate-Palmolive is a company you undoubtedly know. It makes many very popular household products including its eponymous toothpaste and detergent brands, as well as the Science Diet family of pet food.

"But in addition to having a wide stable of recession-resistant brands, the company also has a large presence not just in the U.S. but around the world.

"In fact, more than half of its revenue comes from overseas markets. Latin America accounts for about a third of sales, as does Europe and the South Pacific. Asia/Africa make up the rest.

Continue reading Colgate-Palmolive (CL): A dividend superstar

Colgate-Palmolive (CL): A dividend superstar originally appeared on BloggingStocks on Wed, 08 Apr 2009 11:30:00 EST. Please see our terms for use of feeds.

"The silver lining to the market decline is that some of our favorite stocks have fallen into 'buy' territory," says Nilus Mattive. In his Dividend Superstars he eyes one favorite, Pfizer (NYSE: PFE).

"Pfizer is now trading well below my suggested entry price of $16. In fact, it's back at levels last seen in 1996! The major catalyst for this sharp decline was Pfizer's decision to halve its dividend.

"That came on January 27, just two months after the company said it would simply leave the payment flat this year (which was already the first failure to raise in 42 years).

Continue reading Pfizer (PFE) drops to buy territory

Pfizer (PFE) drops to buy territory originally appeared on BloggingStocks on Tue, 10 Mar 2009 10:30:00 EST. Please see our terms for use of feeds.

"We are seeing quality names at fire-sale prices, and I think you must take advantage of that," says income expert Nilus Mattive in Dividend Superstars. Here's a trio of favorites.

"Pfizer (NYSE: PFE) recently reported great third-quarter results. The company tripled its profits from the same period a year ago. While last year's results were hurt by a one-time charge, Pfizer is obviously seeing continued demand for most of its drugs.

"I consider the stock dirt cheap, and while there is a slim chance of a dividend reduction, the shares absolutely belong in your long-term income portfolio at this level.

"I feel the same way about General Electric (NYSE: GE). While profits were down 22% this quarter, the company still boasts a AAA credit rating and a very attractive yield. It is a solid long-term income holding.

"Huaneng Power (NYSE: HNP) has been punished along with the rest of China's stocks. But things are going well on the fundamental front. The company increased its power generation 12.7% in the first three quarters of 2008, and revenues gained 36.8% over the same period a year earlier.

"It may post a loss because coal prices remain elevated, but I remain bullish on the company's long-term prospects, and consider it the best dividend-paying Chinese stock to own."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

Blue chip dividend stocks on sale: GE, Pfizer & Huaneng originally appeared on BloggingStocks on Tue, 11 Nov 2008 13:36:00 EST. Please see our terms for use of feeds.

"Although Pfizer (NYSE: PFE) recently posted an 18% drop in its first-quarter earnings, I remain a long-term bull on the shares," notes Nilus Mattive in the income and growth oriented Dividend Superstars.

"Results were hurt by tougher generic competition for the company's blood-pressure drug Norvasc and allergy treatment Zyrtec. Pfizer pulled in $0.41 a share in the quarter, but would have earned $0.61 excluding costs associated with two acquisitions.

"A lot of investors are treating the poor earnings as a death knell for the company, especially since Lipitor - PFE's biggest product - will also lose patent protection in 2010. However, I've watched countless drug stocks go through these cycles before, and I continue to believe it's smarter to buy when things look the worst.

"This is still the world's largest drug company ... it still delivers big, fat dividend checks ... and it is making strong moves to reorganize its operations and focus on new drug development. For all those reasons, I remain positive on the shares."

Each day, Steven Halpern's TheStockAdvisors.com offers the latest market commentary and favorite investment ideas from the nation's leading financial newsletter advisors.

Pfizer (PFE): 'Still a favorite' originally appeared on BloggingStocks on Wed, 07 May 2008 11:30:00 EST. Please see our terms for use of feeds.